News | March 17, 2007

A-Fib Ablation System is Focus of New Medtronic Trial

March 19, 2007 — Medtronic Inc. has launched its U.S. pivotal clinical trial for the Cardioblate Surgical Ablation System to treat the cause of permanent atrial fibrillation (AF).

The objective of the CURE-AF (Concomitant Utilization of RadioFrequency Energy for Atrial Fibrillation) Trial is to evaluate the safety and effectiveness of the Cardioblate Surgical Ablation System at reestablishing the normal heart rhythm in patients with permanent AF requiring concomitant open heart surgery utilizing the modified Cox Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs or coronary artery bypass grafts (CABG) procedures.

Cardioblate is an irrigated radiofrequency surgical ablation system used to create lesions on the heart muscle to block irregular signals of the heart, potentially reestablishing normal heart rhythm.

The treatment used during the trial procedure is called irrigated radiofrequency surgical ablation. When providing this treatment, surgeons use irrigated radiofrequency energy from the Medtronic Cardioblate Surgical Ablation System to create lesions on the heart muscle. These lesions are created to block the irregular electrical signals of the heart, which may stop the AF.

To facilitate study enrollment, additional study information for healthcare providers and potential patients, is available at ( Identifier: NCT00431834).

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init